Published online before print December 29, 2005, doi: 10.1161/01.ATV.0000201969.93348.74
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Vascular Biology |
Thromboxane A2/Prostaglandin H2 Receptor Activation Mediates Angiotensin II–Induced Postischemic Neovascularization
From the Cardiovascular Research Center INSERM U689 Lariboisière (F.M., J.-S.S., L.W., M.C., M.D., B.I.L.), Université Paris, Paris, France; and the Institut de Recherches Servier (S.C., T.V., J.P.V.), Suresnes, France.
Correspondance to Bernard Levy or Jean-Sebastien Silvestre, U689-INSERM, Hôpital Lariboisière, 41 Bd de la Chapelle, 75475 Paris cedex 10, France. E-mail levy{at}larib.inserm.fr or Jean-Sebastien.Silvestre@larib.inserm.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Objective— We analyzed the involvement of thromboxane (TX) A2/prostaglandin (PG) H2 (TP) receptor in ischemia-induced neovascularization in mice.
Methods and Results— Unilateral hindlimb ischemia was induced by right femoral artery ligature in male C57BL/6J mice (n=7 per group). Animals were then treated with or without TP receptor antagonist (S18886, 5 or 10 mg/kg per day; ramatroban, 10 mg/kg per day) or aspirin (30 mg/kg per day) in drinking water for 21 days. Hindlimb ischemia raised plasma level of TXB2, the stable metabolite of TXA2, by 4.7-fold. This increase was blocked by aspirin treatment whereas S18886 (5 or 10 mg/kg per day) had no effect. However, neither S 18886 nor aspirin affected postischemic neovascularization. We next assessed the putative involvement of TXA2 signaling in angiotensin II (Ang II) proangiogenic pathway. Ang II (0.3 mg/kg per day) enhanced TXB2 plasma levels by 2.6-fold over that of control (P<0.01). Ang II-induced TXB2 upregulation was reduced by cotreatment with Ang II type I receptor antagonist (candesartan, 20 mg/kg per day). Angiographic score, capillary number, and foot perfusion were improved by 1.7-, 1.7-, and 1.4-fold, respectively, in Ang II-treated mice compared with controls (P<0.05). Ang II proangiogenic effect was associated with a 1.6-fold increase in VEGF-A protein content (P<0.05) and a 1.4-fold increase in the number of Mac-3–positive cells (ie, macrophages) in ischemic areas (P<0.05). Interestingly, treatments with TP receptor antagonists or aspirin hampered the proangiogenic effects of Ang II.
Conclusion— Endogenous activation of TXA2 receptor by eicosanoids did not modulate spontaneous neovascularization in the setting of ischemia. Conversely, TXA2 signaling is involved in Ang II-induced AT1-dependent vessel growth.
Endogenous activation of TXA2 receptor by eicosanoids did not modulate spontaneous neovascularization in the setting of ischemia. In contrast, treatments with TP receptor antagonists or aspirin hampered the proangiogenic effect of Ang II and fully abrogated the Ang II-induced increase in VEGF-A protein content and the number of Mac-3–positive cells.
Key Words: angiogenesis • angiotensin II • ischemia • thromboxane A2
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Neovascularization occurs in response to local tissue ischemia mainly through inflammation and hypoxia signaling. One mechanism by which hypoxia activates blood vessel growth is the increase in hypoxia-inducible factor (HIF-1
) leading to the expression of key growth factors, including vascular endothelial growth factor (VEGF-A) and fibroblast growth factor (FGF).1 Macrophages and T lymphocytes also promote neovascularization in ischemic areas through the release of proinflammatory cytokines, production of matrix metalloproteinases, and expression of angiogenic factors.2–4 Neovascularization takes place in the context of cross-talk involving numerous factors. Among them, hormones such as angiotensin II (Ang II) have been shown to modulate postischemic neovascularization by activation of Ang II type I receptor (AT1) and upregulation of VEGF-A signaling.5,6 Ang II also enhances macrophage infiltration and subsequently inflammation-dependent vessel growth.6–8
Thromboxane A2 (TXA2) is an unstable metabolite of arachidonic acid formed through the cyclooxygenase pathway. TXA2 is released from activated platelets, monocytes, and damaged vessel wall, and causes platelet aggregation, vasoconstriction, and hypertrophy of vascular smooth muscle.9 Action of TXA2 is mediated by thromboxane A2/PG H2 receptor (TP receptor), which are also able to bind other endogenous ligands such as endoperoxides and isoprostanes. TP receptors are widely expressed in the vasculature and exist as 2 isoforms TP and TPß in humans, whereas only TP is present in rodents.10 As in many vasoconstrictive substances, thromboxane A2 (TXA2) has the potential to participate in the regulation of blood vessel growth, but its effect on angiogenesis remain controversial. The TXA2 mimetic IBOP inhibits migration and proliferation of cultured endothelial cells and formation of vascular-like structure in the matrigel model.11,12 TP receptor agonists block the proangiogenic effects of FGF-2.13 TXA2 also abrogates VEGF-A-induced endothelial cell differentiation and migration.14 However, TXA2 overproduction in tumors promotes angiogenesis and tumor development, suggesting that TXA2 is a positive regulator of blood vessel growth.15,16 Similarly, TP blockade using the TP antagonist SQ29548 hampers VEGF-A–induced and FGF-induced endothelial cell migration and corneal neovascularization.17,18
TXA2 levels and TP receptor expression and activation are increased in numerous disease states, including ischemia and inflammation.19 In addition, key angiogenic factors such as VEGF-A have been shown to activate TXA2 signaling.14 Recent reports also suggest that Ang II-related actions may involved activation of TXA2 pathways. Abnormal production of TXA2 is linked to the pathophysiology of renal and Ang II-dependent hypertension, coronary artery spasm, and arterial thrombosis.20–22 In addition, Ang II-dependent contraction of renal afferent arterioles are mediated by TXA2.23 We therefore hypothesized that TXA2-related pathway might be activated during ischemia and may modulate either basal postischemic neovascularization or that induced by Ang II.
To this aim, we analyzed the role of basal endogenous TXA2 signaling in spontaneous neovascularization using the TP antagonist, S 18886, in a model of surgically induced hindlimb ischemia in mice. We also determined the putative involvement of the TXA2-related pathway in the angiogenic effect of Ang II in this context.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Experimental Protocol
This study was conducted in accordance with both institutional guidelines and those formulated by the European community for experimental animal use (L358-86/609EEC). Male C57BL/6J mice (10 weeks old; Iffa Credo, Lyon, France; n=7 per group) were anesthetized (inhalation of isoflurane) and unilateral hindlimb ischemia was induced by right femoral artery ligature, as previously described.3 Mice were randomly assigned to one of the following groups: (1) control group, vehicle; (2) S18886 (TP receptor antagonist, 5 mg/kg per day, (3-((6R)-6{[(4-Chlorophenyl)sulfonyl]amino}-2-methyl-5,6,7,8tetrahydro-1-naphthalenyl propanoic acid, sodium salt, drinking water; Servier), (3) S18886, (10 mg/kg per day, drinking water); (4) ramatroban (TP receptor antagonist, 10 mg/kg per day, drinking water; Bayer); (5) aspirin, (30 mg/kg per day, drinking water; Sigma); (6) Ang II (0.3 mg/kg per day, subhypertensive dose delivered by osmotic minipump); (7) Ang II (0.3 mg/kg per day) plus S18886 (10 mg/kg per day); (8) Ang II (0.3 mg/kg per day) plus ramatroban (10 mg/kg per day); (9) Ang II (0.3 mg/kg per day) plus aspirin (30 mg/kg per day); and (10) Ang II (0.3 mg/kg per day) plus candesartan (AT1 receptor blocker, 20 mg/kg per day, drinking water; Astra). Doses were chosen on the basis of previous experimental protocols in mice.24,25 Sham-operated animals served as a control group without hindlimb ischemia.
Quantification of Neovascularization
Microangiography
After 21 days of treatment, vessel density was evaluated by high-definition microangiography using Barium sulfate (1 g/mL) injected in the abdominal aorta, followed by image acquisition with a digital X-ray transducer and computerized quantification of vessel density expressed as a percentage of pixels per image occupied by vessels in the quantification area.3
Capillary Density
Microangiographic analysis was completed by assessment of capillary density, as previously described.3 Ischemic and nonischemic gastrocnemius were dissected and progressively frozen in isopentane solution cooled in liquid nitrogen (LN2). Sections (7 µm) were incubated with rabbit polyclonal antibody directed against total fibronectin (dilution, 1:50) to identify capillaries. Capillary density was then calculated in randomly chosen fields of a definite area using Optilab/Pro software.
Laser Doppler Perfusion Imaging
We gathered functional evidence for ischemia-induced change in mouse hindlimb vascularization. Blood perfusion in the paw was assessed through laser Doppler imaging, as previously described.3 For each animal, perfusion was measured in both the ischemic and nonischemic paw and the ratio was calculated. Results were expressed as the mean ratio of ischemic to nonischemic values for each experimental group.
Determination of VEGF-A Expression
VEGF-A protein expression was determined by Western blot in ischemic and nonischemic legs, as previously described.3 Gastrocnemius samples were homogenized in a lysis buffer supplemented with protease inhibitor. Samples were loaded on an SDS-PAGE gel (10%) and protein transferred to a nitrocellulose sheet (Hybond enhanced chemiluminescence [ECL]; Amersham). Blots were incubated with antibodies against VEGF-A (Santa Cruz Biotechnology; dilution of 1:2,000). As a protein loading control, membranes were stripped, incubated with a goat polyclonal antibody directed against total actin (Santa Cruz Biotechnology; dilution of 1:5000). Specific protein was detected by chemiluminescence reaction (ECL+ kit; Amersham).
Determination of Plasma TXB2 Concentration and Tissue Ang II Levels
At time of euthanization, blood was collected and plasma samples were recovered by centrifugation without clot and stored at –20°C until analysis. Plasma TXB2 concentration was measured using a commercially available enzyme immunoassay kit (Cayman Chemical). Ang II tissue content was measured in ischemic and non ischemic gastrocnemius using Ang II enzyme immunoassay kit, according to manufacturer instructions (Spi Bio).
Evaluation of Macrophage Number (Mac-3–Positive Macrophages)
Frozen tissue sections (7 µm) were incubated with rat polyclonal antibody directed against Mac-3 (1:50; BD Pharmingen). After incubation with a biotinylated anti-rat IgG, immunostains were visualized by using avidin-biotin horseradish peroxidase visualization systems (Vectastain ABC kit elite; Vector Laboratories).
Statistical Analysis
Results are expressed as mean±SEM. One-way analysis of variance ANOVA was used to compare each parameter. Post hoc Bonferroni t test comparisons were then performed to identify which group differences account for the significant overall ANOVA. A value of P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Ischemia Increases Ang II and TXA2 Plasma Levels
Plasma levels of TXB2, the stable metabolite of TXA2 were assayed by enzyme-linked immunosorbent assay (ELISA). Hindlimb ischemia raised TXB2 plasma levels by 4.7-fold compared with sham nonischemic animals (P<0.01; Figure 1A). As expected, treatment of ischemic mice with S 18886 at 5 or 10 mg/kg per day did not significantly affect TXB2 plasma levels.24,25 In contrast, aspirin administration abrogated ischemia-induced upregulation of TXB2 plasma levels (P<0.01 versus untreated mice with hindlimb ischemia). Ischemia increases TXB2 plasma levels, suggesting that the TXA2-related pathway is activated and may affect neovascularization in this setting.
|
Basal TXA2 Signaling Does Not Modulate Postischemic Neovascularization
To analyze the role of activated TXA2 pathway in postischemic neovascularization, mice with hindlimb ischemia were treated with or without TP receptor blockers. TXA2 pathway inhibition with aspirin (30 mg/kg per day) was the negative control. However, S 18886 or ramatroban administration did not affect the ischemic to nonischemic angiographic score (Figure 1B) and foot perfusion ratio (Figure 1C). Therefore, TXA2 signaling is not involved in the spontaneous neovascularization in the setting of ischemia. Aspirin was also devoid of any effect on these parameters.
Involvement of TXA2 in Ang II Proangiogenic Effect
Alternatively, TXA2 signaling may modulate the effect of exogenously added proangiogenic factor. TXA2 has been shown to participate in Ang II-related effects on cardiovascular homeostasis. In addition, we showed that ischemia raised Ang II tissue levels by 1.4-fold 7 days after the onset of ischemia (18.7±2.5 pg/mg proteins versus 13.4±2.1 pg/mg proteins in ischemic gastrocnemius versus non ischemic gastrocnemius; P<0.05, n=6). Exogenous administration of Ang II, by osmotic minipump, enhances Ang II tissue contents by 2.9-fold (54.2±14.2 pg/mg proteins; P<0.05 versus untreated ischemic gastrocnemius). We therefore analyzed the putative involvement of TXA2 in Ang II proangiogenic effect in the setting of ischemia.
TXA2 Synthesis and Ang II
In the absence of ischemia, Ang II alone increases TXB2 plasma levels by 1.5-fold compared with untreated mice (1.9±0.3 ng/mL versus 1.3±0.2 ng/mL in Ang II-treated mice versus untreated animals, respectively; P<0.05, n=5 per group). In presence of ischemia, Ang II further enhanced TXB2 plasma levels by 2.6-fold compared with untreated ischemic mice (12.8±2.2 ng/mL versus 4.9±0.6 ng/mL in Ang II-treated mice compared with untreated animals, respectively; P<0.01). Administration of AT1 receptor blocker reduced TXB2 to untreated levels (5.4±1.1 ng/mL versus 12.8±2.2 ng/mL in Ang II and candesartan-treated mice compared with Ang II-treated animals; P<0.05). Treatment with S 18886 did not affect the Ang II-induced increase in TXB2 plasma levels (12.2±1.7 ng/mL). Aspirin administration hampered the increase in TXB2 plasma levels observed after Ang II treatment (6.8±1.0 ng/mL versus 12.8±2.2 ng/mL in Ang II-treated and aspirin-treated mice compared with Ang II-treated animals; P<0.05). Taken together, these results suggest that Ang II upregulated TXA2 levels through AT1-dependent mechanism.
TXA2 and Ang II Proangiogenic Effect
The angiographic score, capillary number, and paw perfusion was improved by 1.7-, 1.7-, and 1.4-fold, respectively in Ang II-treated mice when compared with controls (P<0.05; Figure 2). S 18886, ramatroban, and aspirin treatments hampered the Ang II-induced increase in the neovascularization process (P<0.05 versus Ang II-treated mice). AT1 receptor blockade also reduced Ang II-induced activation of postischemic neovascularization (Figure 2).
|
TXA2 and Ang II Signaling
Inflammation-Related Pathway
Treatment with Ang II enhanced the number of Mac-3–positive cells (ie, macrophages) in the ischemic hindlimbs (P<0.05 versus control mice, n=5). Mac-3–positive cells were counted in the adventitia and perivascular space of arteries (Figure 3A). S 18886, ramatroban, and aspirin prevented Ang II-induced increase in macrophage infiltration. Finally, AT1 inhibition also abrogated Ang II proinflammatory-related effects. VEGF-A
|
Ang II proangiogenic effect was associated with a 1.6-fold increase in VEGF-A protein content when compared with untreated animals (P<0.05, n=5) (Figure 3B). This upregulation was prevented by administration of S 18886 (10 mg/kg per day), ramatroban (10 mg/kg per day), aspirin, or AsT1 receptor blocker (P<0.05 versus Ang II-treated mice). As a protein loading control, membranes were stripped and incubated with a goat polyclonal antibody directed against total actin (Figure 3B).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The main results of this study are that TXA2 does not modulate spontaneous neovascularization reaction after hindlimb ischemia. Conversely, TXA2 signaling is involved in Ang II-induced AT1-dependent vessel growth in ischemic areas.
The role of TXA2 signaling in angiogenesis remains controversial. TP receptor activation has been shown to either activate or inhibit endothelial cell proliferation and angiogenesis in different experimental models.17,18 This apparent opposite action is likely related to the existence of 2 TP isoforms, and ß, with opposite effects. TPß expression and subsequent signaling result in inhibition of angiogenesis, whereas TP activates the angiogenic phenotype.13,14 Animal models lack TPß, whereas cultured endothelial human cells express both isoforms and, in these cells, TPß-related effects overcome that of TP, resulting in inhibition of the angiogenic reaction.10
In this study, we hypothesized that the TXA2-related pathway may affect the proangiogenic effect of exogenously added angiogenic factors, such as Ang II. In absence of ischemia, Ang II improves TXB2 plasma levels but is unable to modulate capillary number. Similarly, normal arteries are known to be totally immune against exogenous growth factors likely because growth factor receptors are rapidly downregulated.26,27 In contrast, in the setting of ischemia, we showed that Ang II further increases TXB2 plasma level through AT1-dependent mechanism and that TP blockers administration hamper Ang II-induced vessel growth. In addition, TP receptor antagonists totally abrogate the Ang II-induced VEGF-A upregulation suggesting that TXA2 is an upstream regulator of VEGF-A protein levels. S 18886 and ramatroban also reduce the number of Mac-3–positive cells in ischemic areas, demonstrating that TP receptor activation is involved in Ang II proinflammatory effect. Similarly, a specific involvement of prostanoids has been demonstrated in IL-1ß–induced angiogenesis.24 These results are also in line with previous studies showing that TXA2 mediates Ang II-related effects. TXA2 triggers Ang II-dependent vasoconstriction in the kidney vasculature23 and in rat hindlimb.28 TXA2 is also involved in Ang II-induced vascular smooth muscle cell (VSMC) proliferation.29,30 Aspirin treatment abrogates Ang II-induced neovascularization, it is therefore likely that other TP receptor ligands, isoprostanes or HETE, do not interfere in this process. Taken together, our results underline that TXA2/TP signaling mediates Ang II proangiogenic effect in ischemic tissue.
However, TP receptor inhibition, in absence of exogenous addition of Ang II, does not modulate spontaneous neovascularization. Similarly, aspirin administration does not affect vessel growth, as previously described.31 The reason for this discrepancy is unclear. One can first hypothesize that ischemia-induced Ang II upregulation may increase TXA2 tissue contents to levels that are insufficient to modulate new vessel growth in ischemic areas. In support of this view, exogenous administration of Ang II markedly enhances TXB2 plasma levels compared with untreated ischemic mice. In this context, Ang II-induced TXA2 upregulation participates to postischemic neovascularization. Second, numerous pathways and cell types are involved in spontaneous vessel growth in vivo. Exogenous FGF enhances neovascularization in animal models of peripheral arterial occlusion, yet, the angiogenic and arteriogenic processes are unaffected in mice lacking endogenous FGF-2.32,33 Hence, S18886 treatment alone may underestimate the importance of endogenous TXA2 because of some sort of compensatory response by other proangiogenic pathways. Finally, TXA2 may play a permissive role of in the proangiogenic effect of Ang II and subsequently may modulate vessel growth in pathological situations associated with Ang II level upregulation.
In conclusion, endogenous activation of TXA2 receptor by eicosanoids did not modulate spontaneous neovascularization in the setting of ischemia. In contrast, TP receptor activation is involved in Ang II proangiogenic effect. This study also highlights the concept that TP receptor inhibition might be of interest in the treatment of diseases associated with Ang II overproduction, such as diabetic retinopathy.
Received September 8, 2005; accepted December 15, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
- Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–660.[CrossRef][Medline] [Order article via Infotrieve]
- Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest. 1998; 101: 40–50.[Medline] [Order article via Infotrieve]
- Silvestre JS, Mallat Z, Duriez M, Tamarat R, Bureau MF, Scherman D, Duverger N, Branellec D, Tedgui A, Levy BI. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ Res. 2000; 87: 448–452.
[Abstract/Free Full Text] - Silvestre JS, Mallat Z, Tamarat R, Duriez M, Tedgui A, Levy BI. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ Res. 2001; 89: 259–264.
[Abstract/Free Full Text] - Tamarat R, Silvestre JS, Kubis N, Benessiano J, Duriez M, deGasparo M, Henrion D, Levy BI. Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. Hypertension. 2002; 39: 830–835.
[Abstract/Free Full Text] - Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S, Imaizumi T. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest. 2002; 109: 603–611.[CrossRef][Medline] [Order article via Infotrieve]
- Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest. 2002; 82: 747–756.[Medline] [Order article via Infotrieve]
- Toko H, Zou Y, Minamino T, Masaya M, Harada M, Nagai T, Sugaya T, Terasaki F, Kitaura Y, Komuro I. Angiotensin II type 1a receptor is involved in cell infiltration, cytokine production, and neovascularization in infarcted myocardium. Arterioscler Thromb Vasc Biol. 2004; 24: 664–670.
[Abstract/Free Full Text] - Kinsella BT. Thromboxane A2 signalling in humans: a ‘Tail’ of two receptors. Biochem Soc Trans. 2001; 29: 641–654.[CrossRef][Medline] [Order article via Infotrieve]
- Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001; 108: 25–30.[CrossRef][Medline] [Order article via Infotrieve]
- Ashton AW, Yokota R, John G, Zhao S, Suadicani SO, Spray DC, Ware JA. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem. 1999; 274: 35562–35570.
[Abstract/Free Full Text] - Gao Y, Yokota R, Tang S, Ashton AW, Ware JA. Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thromboxane A(2). Circ Res. 2000; 87: 739–745.
[Abstract/Free Full Text] - Ashton AW, Cheng Y, Helisch A, Ware JA. Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alpha(v)beta3. Circ Res. 2004; 94: 735–742.
[Abstract/Free Full Text] - Ashton AW, Ware JA. Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res. 2004; 95: 372–379.
[Abstract/Free Full Text] - Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B, May F, Flatau G, Mareel M, Gespach C, Emami S. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J. 2001; 15: 1517–1528.
[Abstract/Free Full Text] - Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, Nukiwa T. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 2002; 62: 63–66.
[Abstract/Free Full Text] - Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 1999; 59: 4574–4577.
[Abstract/Free Full Text] - Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y, Honn KV. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun. 2000; 267: 245–251.[CrossRef][Medline] [Order article via Infotrieve]
- Shen RF, Tai HH. Thromboxanes: synthase and receptors. J Biomed Sci. 1998; 5: 153–172.[CrossRef][Medline] [Order article via Infotrieve]
- Mistry M, Nasjletti A. Contrasting effect of thromboxane synthase inhibitors and a thromboxane receptor antagonist on the development of angiotensin II-salt-induced hypertension in rats. J Pharmacol Exp Ther. 1990; 253: 90–94.
[Abstract/Free Full Text] - Dai FX, Skopec J, Diederich A, Diederich D. Prostaglandin H2 and thromboxane A2 are contractile factors in intrarenal arteries of spontaneously hypertensive rats. Hypertension. 1992; 19: 795–798.
[Abstract/Free Full Text] - Lin L, Balazy M, Pagano PJ, Nasjletti A. Expression of prostaglandin H2-mediated mechanism of vascular contraction in hypertensive rats. Relation to lipoxygenase and prostacyclin synthase activities. Circ Res. 1994; 74: 197–205.
[Abstract/Free Full Text] - Wang D, Chabrashvili T, Wilcox CS. Enhanced contractility of renal afferent arterioles from angiotensin-infused rabbits: roles of oxidative stress, thromboxane prostanoid receptors, and endothelium. Circ Res. 2004; 94: 1436–1442.
[Abstract/Free Full Text] - Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000; 20: 1724–1728.
[Abstract/Free Full Text] - Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296: 539–541.
[Abstract/Free Full Text] - Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res. 2004; 95: 449–458.
[Abstract/Free Full Text] - Hoefer IE, van Royen N, Buschmann IR, Piek JJ, Schaper W. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res. 2001; 49: 609–617.
[Abstract/Free Full Text] - Fukuhara M, Neves LA, Li P, Diz DI, Ferrario CM, Brosnihan KB. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo. J Hypertens. 2001; 19: 561–566.[CrossRef][Medline] [Order article via Infotrieve]
- Young W, Mahboubi K, Haider A, Li I, Ferreri NR. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res. 2000; 86: 906–914.
[Abstract/Free Full Text] - Sachinidis A, Flesch M, Ko Y, Schror K, Bohm M, Dusing R, Vetter H. Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension. 1995; 26: 771–780.
[Abstract/Free Full Text] - Emanueli C, Van Linthout S, Salis MB, Monopoli A, Del Soldato P, Ongini E, Madeddu P. Nitric oxide-releasing aspirin derivative, NCX 4016, promotes reparative angiogenesis and prevents apoptosis and oxidative stress in a mouse model of peripheral ischemia. Arterioscler Thromb Vasc Biol. 2004; 24: 2082–2087.
[Abstract/Free Full Text] - Sullivan CJ, Doetschman T, Hoying JB. Targeted disruption of the Fgf2 gene does not affect vascular growth in the mouse ischemic hindlimb. J Appl Physiol. 2002; 93: 2009–2017.
[Abstract/Free Full Text] - Yang HT, Deschenes MR, Ogilvie RW, Terjung RL. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ Res. 1996; 79: 62–69.
[Abstract/Free Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||